[Biochemical prognostic factors of ovarian carcinoma].
In therapy decision and monitoring of ovarian cancer clinicians use clinical and histomorphological criteria. Thus, intensive research in tumor biology of ovarian cancer leads to the development of biochemical parameters and a deeper understanding of proliferation and metastasis in-vitro testing of anticancer drugs is one way to achieve a dynamic model to tumor growth. The expression of the erb B oncogene family, especially erb-B-2, is an important finding for the estimation of the potential of an ovary tumor to grow at metastatic sites. The erb B oncogenes encode membrane-growth-factor-receptors functioning in signal transduction for cell growth stimulation. In several studies disease-free survival of advanced ovarian carcinoma was significantly related to the extent of erb-B-2 amplification and/or over-expression. High erb-B-2 expression in the tumor at time of primary treatment indicated a positive second-look-laparotomy. New experimental approaches for alternative therapies use erb-B-2 as the target for interference of tumor cell proliferation.
Brandt
B
B
Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälischen Wilhelms-Universität Münster.
D014408:Biomarkers, Tumor / Q000235:genetics*; D002455:Cell Division / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018432:Drug Resistance, Multiple / Q000235:genetics; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D010052:Ovariectomy; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D012086:Reoperation
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases
Biochemische Prognosefaktoren des Ovarialkarzinoms.